Applying science to care.

Medavera identifies gaps in knowledge and care, methodically researches the subject matter, identifies the top experts to guide the content, and then utilizes a format that will provide the best learning opportunity. We are always looking for new teaching methods and technologies in order to offer stimulating and actionable medical education. Medical education must be meaningful to become applied to clinical practice. Great content, respected leaders, and interesting formats create successful interactions and learning.
FEATURED PROJECT

Hyperphosphatemia in CKD: Cases for Improving Compliance and Outcome
September 13, 2016
5 PM ET

KidneyU.com

This accredited educational webinar presented by Drs. Ellie Kelepouris, Kathleen Hill Gallant, and Debra J. Hain, will explore hyperphosphatemia in CKD patients, compare and contrast new phosphate binders, and identify new strategies to improve patient adherence and outcome for CKD patients with hyperphosphatemia.

Planned and developed by Medavera, financial support for this independent medical education program was provided by Keryx Biopharmaceuticals, Inc.

There is no charge for the program or certificate, but registration is required for the webinar, access to the slides, and CME assessment.

THE MEDICAL NEWS
BANGKOK (Reuters) - Thailand is investigating four suspected cases of Zika-related microcephaly in three babies and a 36-week old unborn baby, the public health minister said on Tuesday, in what could be the first cases of Zika-linked microcephaly in Southeast Asia.... (Reuters) - Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.... (Reuters) - Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, was not found superior to Takeda Pharmaceutical Co Ltd's Velcade in a late-stage study in previously untreated patients.... (Reuters) - Mylan NV faced questions on Monday about the profit on its EpiPen emergency allergy treatment, following a report that the company makes 60 percent more on the injector than it had told Congress.... Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum.... (Reuters Health) - Most American teenagers don’t get enough exercise, and they often stick with their sedentary ways as they enter adulthood, a U.S. study suggests.... (Reuters Health) - The proportion of U.S. babies born suffering from withdrawal syndrome after exposure to heroin or prescription opiates in utero has more than doubled in less than a decade, a study suggests.... (Reuters Health) - People with cancer may overestimate the possible benefits to them of participating in an early trial of a new medicine, even after talking with a doctor about what to expect, according to a new study from the U.K.... (Reuters Health) - For women with a history of miscarriage, experiencing nausea and vomiting during subsequent pregnancy attempts is linked to higher odds of success, a U.S. study suggests.... (Reuters) - Kite Pharma Inc on Monday said its experimental CAR T-cell therapy, which helps the immune system fight cancer, was highly effective in treating aggressive non-Hodgkin lymphoma, although two deaths were related to the drug, according to interim data from a midstage trial....